Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with castrate-resistant prostate cancer (a form of prostate cancer that keeps growing despite very low testosterone levels) that is getting worse, shown by rising PSA blood test results, growing tumours on scans, new or worsening bone disease, or new lesions found on a special PSMA PET scan
- People whose cancer has spread to other parts of the body, confirmed by CT, MRI, bone scan, or PSMA PET imaging
- People whose PSMA PET scan shows that all detectable spread of cancer is PSMA-positive (a specific marker visible on this type of scan), with no lesions that are PSMA-negative
- People whose cancer has continued to grow after hormone-blocking treatment (ADT) and at least one hormone therapy drug such as enzalutamide, apalutamide, darolutamide, or abiraterone
- People who have been receiving bone-protecting medication (such as zoledronic acid or denosumab) for at least 4 weeks before starting the study drug, unless there is a medical reason they cannot take these medications
- People living with HIV may be considered if their HIV has been undetectable (fewer than 50 copies/mL) within the past 6 months and they have been on a stable HIV treatment regimen for at least 6 months (confirm with trial site)
- For one specific part of the trial only (Part 3): People who have previously been treated with a specific type of radioactive therapy called Lu-177-PSMA, and who have received no more than one course of taxane-based chemotherapy
Who may not be able to join:
- People whose bone scan shows a pattern called a "superscan," where cancer has spread very extensively throughout the bones (confirm with trial site)
- People who have another cancer that is still active or has required treatment within the past 3 years (other than the prostate cancer being studied), especially if it could affect life expectancy or make it harder to assess the prostate cancer
- People who have previously received platinum-based chemotherapy
- People who have previously taken PARP inhibitor drugs, such as olaparib or rucaparib
- People who have previously been treated with certain radioactive therapies, including Radium-223, Actinium-225, Strontium-89, Samarium-153, Rhenium-186, or Rhenium-188
- People taking blood-thinning or anti-clotting medications (such as aspirin or anti-inflammatory drugs) who are unable to stop taking them if their platelet count drops too low
- For one specific part of the trial only (Part 2): People who have received any chemotherapy for their castrate-resistant prostate cancer, or any radioactive drug therapy, or any treatment specifically targeting the PSMA protein (note: taxane chemotherapy given for an earlier stage of prostate cancer may be allowed if it was stopped more than one year before joining)
- For one specific part of the trial only (Part 3): People who have received PSMA-targeted treatments such as antibody-drug combinations or CAR-T cell therapy (previous Lu-177-PSMA radioligand therapy is allowed in this part)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: CONVERGE01
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: Visual evaluation on whole body planar scans (days 1 and 4) with comparison to reference scans for the presence of radiolabeled rosopatamab textraxetan in organs of interest (e.g., liver, circulation, spleen) to determine biodistribution; Part 2: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) overall, by severity, and leading to discontinuation of study intervention; Part 2: Proportion of participants who achieve a greater than or equal to 50% decline in prostate-specific antigen (PSA50); Part 3: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) o...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.